The 18th Annual International Pachyonychia Congenita Consortium (IPCC) Symposium
Wednesday, May 18, 2022
8am-12pm PDT
(9am-1pm MDT, 10am-2pm CDT, 11am-3pm EDT, 4pm-8pm UK, 5pm-9pm France, 6pm-10pm Israel)
To be held in person with the Society for Investigative Dermatology (SID) Annual Meeting at the Oregon Convention Center AND virtually through Zoom.
All researchers, clinicians, and industry representatives interested in PC (and other rare skin conditions with PPK) are invited to join at no cost.
Please contact us at info@pachyonychia.org with questions.
For those planning to attend in person:
- PC Project is hosting a dinner Tuesday, May 17th (the night before the meeting) for any interested attendees. We will contact you with details once you have registered.
- The SID is requiring proof of full COVID-19 vaccination (plus booster) for admittance to ALL SID in-person meetings and events.
- The headquarter hotel for the 2022 SID Annual Meeting is the Hyatt Regency Portland at the Oregon Convention Center. Click here to reserve your hotel room at the Hyatt Regency Portland.
IPCC Symposium Program
Click here for the full program with abstracts and bios of the presenters.
Leading the way to a cure: Basic research track
Chair: C. David Hansen, MD
8:00 AM PDT
Welcome
Footprints: On our way to a cure through the power of the IPCC and the International PC Research Registry
Janice N. Schwartz, BA
Executive Director, Pachyonychia Congenita Project
8:15 AM PDT
PPKs: Gluing the pieces together
Eli Sprecher, MD, PhD
Chair, Division of Dermatology, Deputy Director General for R&D and Innovation, Tel Aviv Sourasky Medical Center, Frederick Reiss Professor of Dermatology, Sackler Faculty of Medicine, Tel Aviv University; IPCC Chair
8:30 AM PDT
Mouse models for pachyonychia congenita and palmoplantar keratoderma
Pierre A. Coulombe, PhD
G. Carl Huber Professor and Chair, Department of Cell & Developmental Biology, University of Michigan Medical School
8:45 AM PDT
Impact on daily plantar pain and activity levels in pachyonychia congenita measured through a wristband activity tracker
Julianne M. Falotico, BA
Renaissance School of Medicine at Stony Brook University
Shari R. Lipner, MD, PhD
Associate Professor of Clinical Dermatology, Director, Nail Division, Weill Cornell Medicine
8:55 AM PDT
PPK and cysts
Edel O’Toole MD, PhD, FRCPI, FRCP
Professor of Molecular Dermatology and Centre Lead, Centre for Cell Biology and Cutaneous Research, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London
Neil Rajan, MD, PhD
Senior Lecturer and Honorary Consultant Dermatologist, Translational and Clinical Research Institute, Newcastle University
9:10 AM PDT
PPK syndromes: Focus on iRhom2 and tylosis with oesophageal cancer
David P. Kelsell, PhD
Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London
9:25 AM PDT
Lysosomal function in pachyonychia congenita pathogenesis
Nicole Schwarz, PhD
RWTH Aachen University, Institute of Molecular and Cellular Anatomy
9:40 AM PDT
Probing the functional link between pachyonychia congenita-associated keratins and cell mechanics
Benjamin A. Nanes, MD, PhD
Instructor of Dermatology University of Texas Southwestern Medical Center
9:55 AM PDT
Pain mechanisms in palmoplantar keratodermas
Michael Caterina, MD, PhD
Department of Neurosurgery, Johns Hopkins School of Medicine
10:10 AM PDT Break
Finding the way to a cure: Clinical research track
Chair: Robyn Hickerson, PhD
10:15 AM PDT
Topical erlotinib as a new approach for treating keratinopathies
Amy Paller, MD
Walter J. Hamlin Professor and Chair of Dermatology and Professor of Pediatrics; Director, Skin Biology and Diseases Resource-based Center, Northwestern University Feinberg School of Medicine
Bethany E. Perez White, PhD
Assistant Professor, Department of Dermatology, Feinberg School of Medicine, Northwestern University
10:35 AM PDT
Systemic erlotinib for PPK
Alain Hovnanian, MD, PhD
Professor of Genetics and Dermatology, INSERM, Imagine Institute for Genetic Diseases, Necker Hospital for Sick Children, Paris University
10:50 AM PDT
PC Project and Palvella Therapeutics collaboration: Update on QTORIN Rapamycin development program for pachyonychia congenita
Wes Kaupinen, MBA
Founder and CEO, Palvella Therapeutics
11:05 AM PDT
The Feldan Shuttle: Leading the future of intracellular delivery
Vincent Ménard, PhD, MBA, CFA
VP Finance & Business Development, Feldan Therapeutics
11:20 AM PDT
Development of topical siRNA formulations for treatment of genetic skin disorders including PC
Roger Kaspar, PhD
Founder and CEO, Ayni Therapeutics
Shak Lakhani
Co-founder and CEO, Avro Life Science
11:35 AM PDT
Toward a chemical compound therapy for EBS
Thomas M. Magin, PhD
Professor of Cell and Developmental Biology, University of Leipzig, Institute of Biology
11:50 AM PDT
Discussion/wrap up
C. David Hansen, MD
Dermatology Professor, University of Utah and PI of the International Pachyonychia Congenita Research Registry
12:00 PM PDT Lunch for pre-registered in-person attendees
12:10 PM PDT
PC Project’s Medical and Scientific Advisory Board (MSAB) Meeting
Chair: Eli Sprecher, MD, PhD
